Equillium (NASDAQ:EQ) Receives Market Perform Rating from Leerink Partners

Leerink Partners restated their market perform rating on shares of Equillium (NASDAQ:EQ) in a research report released on Friday, Marketbeat reports. They currently have a $1.00 price objective on the stock, down from their prior price objective of $3.00.

Equillium Stock Down 16.9 %

Shares of EQ stock opened at $0.41 on Friday. Equillium has a 12 month low of $0.37 and a 12 month high of $2.43. The firm has a market cap of $14.36 million, a PE ratio of -2.90 and a beta of 1.87. The stock has a 50 day moving average of $0.76 and a 200-day moving average of $0.79.

Equillium (NASDAQ:EQ) last released its earnings results on Thursday, March 27th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. The firm had revenue of $4.39 million during the quarter. Equillium had a negative net margin of 10.05% and a negative return on equity of 20.68%. As a group, equities analysts predict that Equillium will post 0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Equillium

A hedge fund recently raised its stake in Equillium stock. DCF Advisers LLC increased its stake in shares of Equillium, Inc. (NASDAQ:EQ) by 91.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,947 shares of the company’s stock after buying an additional 29,985 shares during the quarter. DCF Advisers LLC owned 0.18% of Equillium worth $47,000 at the end of the most recent reporting period. 27.05% of the stock is currently owned by institutional investors.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.